Filing Flows › CytomX Therapeutics (CTMX) › Q1 2025
CytomX Therapeutics (CTMX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
CytomX Therapeutics (CTMX) reported revenue of $50.9M for the first quarter 2025 (Q1 2025), +23% from a year earlier and +34% from the quarter before. Operating margin was 44.4%, net earnings $23.5M (46.2% of revenue).
CytomX Therapeutics, Q1 2025: revenue $50.9M (+23% year over year), operating margin 44.4%, net earnings $23.5M, operating cash flow −$21.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $50.9M | +34% | +23% |
| Operating profit | $22.6M | +28% | +94% |
| Net earnings | $23.5M | +25% | +71% |
| Operating cash flow | −$21.0M | — | — |
What changed
Revenue was $50.9M in Q1 2025, up 23% year over year and up 34% from the previous quarter.
Operating profit was $22.6M, a 44.4% margin (up 16.3 points year over year). Of the extra revenue versus a year earlier, 116% reached operating profit, above the 28% margin then. Total costs fell 5% while revenue rose 23%. The fastest-growing cost line was General & admin (+22%). Net earnings were $23.5M, up 71% year over year. The effective tax rate was 0.3%.
Operating cash flow was −$21.0M. Non-cash charges added back $2.0M of share-based compensation. Working capital and other items used $46.6M. Capital expenditures of $119K exceeded it, leaving free cash flow of −$21.2M.
Questions
What was CytomX Therapeutics' revenue in the first quarter 2025?
CytomX Therapeutics (CTMX) reported revenue of $50.9M for the first quarter 2025 (Q1 2025), +23% from a year earlier and +34% from the quarter before.
Was CytomX Therapeutics profitable in the first quarter 2025?
Operating profit was $22.6M (44.4% of revenue) and net earnings $23.5M.